Division of Cardiothoracic Surgery, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colo.
Division of Cardiothoracic Surgery, Department of Surgery, University of Virginia, Charlottesville, Va.
J Thorac Cardiovasc Surg. 2024 May;167(5):1833-1841.e2. doi: 10.1016/j.jtcvs.2022.12.013. Epub 2022 Dec 21.
We sought to determine the impact of right ventricular dysfunction on the outcomes of mechanically ventilated patients with COVID-19 requiring veno-venous extracorporeal membrane oxygenation.
Six academic centers conducted a retrospective analysis of mechanically ventilated patients with COVID-19 stratified by support with veno-venous extracorporeal membrane oxygenation during the first wave of the pandemic (March to August 2020). Echocardiograms performed for clinical indications were reviewed for right and left ventricular function. Baseline characteristics, hospitalization characteristics, and survival were compared.
The cohort included 424 mechanically ventilated patients with COVID-19, 126 of whom were cannulated for veno-venous extracorporeal membrane oxygenation. Right ventricular dysfunction was observed in 38.1% of patients who received extracorporeal membrane oxygenation and 27.4% of patients who did not receive extracorporeal membrane oxygenation with an echocardiogram. Biventricular dysfunction was observed in 5.5% of patients who received extracorporeal membrane oxygenation. Baseline patient characteristics were similar in both the extracorporeal membrane oxygenation and non-extracorporeal membrane oxygenation cohorts stratified by the presence of right ventricular dysfunction. In the extracorporeal membrane oxygenation cohort, right ventricular dysfunction was associated with increased inotrope use (66.7% vs 24.4%, P < .001), bleeding complications (77.1% vs 53.8%, P = .015), and worse survival independent of left ventricular dysfunction (39.6% vs 64.1%, P = .012). There was no significant difference in days ventilated before extracorporeal membrane oxygenation, length of hospital stay, hours on extracorporeal membrane oxygenation, duration of mechanical ventilation, vasopressor use, inhaled pulmonary vasodilator use, infectious complications, clotting complications, or stroke. The cohort without extracorporeal membrane oxygenation cohort demonstrated no statistically significant differences in in-hospital outcomes.
The presence of right ventricular dysfunction in patients with COVID-19-related acute respiratory distress syndrome supported with veno-venous extracorporeal membrane oxygenation was associated with increased in-hospital mortality. Additional studies are required to determine if mitigating right ventricular dysfunction in patients requiring veno-venous extracorporeal membrane oxygenation improves mortality.
我们旨在确定右心室功能障碍对需要静脉-静脉体外膜肺氧合(ECMO)支持的 COVID-19 机械通气患者结局的影响。
6 家学术中心对大流行第一波期间(2020 年 3 月至 8 月)根据是否接受静脉-静脉 ECMO 支持对 COVID-19 机械通气患者进行了回顾性分析。回顾了因临床指征进行的超声心动图检查以评估右心室和左心室功能。比较了基线特征、住院特征和生存率。
该队列包括 424 例 COVID-19 机械通气患者,其中 126 例接受了静脉-静脉 ECMO 插管。接受 ECMO 治疗的患者中有 38.1%和未接受 ECMO 治疗的患者中有 27.4%存在右心室功能障碍。接受 ECMO 治疗的患者中有 5.5%存在双心室功能障碍。在按是否存在右心室功能障碍分层的 ECMO 和非 ECMO 两组患者中,基线患者特征相似。在 ECMO 组中,右心室功能障碍与更多地使用正性肌力药物(66.7% vs. 24.4%,P<.001)、出血并发症(77.1% vs. 53.8%,P=.015)和更差的生存相关(39.6% vs. 64.1%,P=.012),而与左心室功能障碍无关。在接受 ECMO 治疗之前,通气时间、住院时间、ECMO 时间、机械通气时间、血管加压素使用、吸入肺血管扩张剂使用、感染性并发症、凝血并发症或中风无显著差异。没有 ECMO 组在院内结局方面没有统计学上的显著差异。
COVID-19 相关急性呼吸窘迫综合征患者接受静脉-静脉 ECMO 支持时存在右心室功能障碍与院内死亡率增加相关。需要进一步研究以确定是否减轻需要静脉-静脉 ECMO 的患者的右心室功能障碍是否可以改善死亡率。